Search

News | 2023.04.17

ComCor study: the impact of variants and circumstances of infection on the COVID-19 incubation period

The link between the viral variant and length of the COVID-19 incubation period is still a matter of debate. Scientists from the Institut Pasteur conducted a survey of thousands of volunteers for more than a year to provide an answer.

Page avancée | 2020.06.17

All SARS-CoV-2 / COVID-19 from the Institut Pasteur

Vidéo | 2020.02.20

COVID-19 : What we have learnt as of 20 February 2020

Article | 2020.06.22

Fiche maladie redirect en Sars-CoV-2 / Covid-19

Article | 2020.07.07

COVID-19 - The Bioinformatics and Biostatistics Hub on the front line

News | 2023.02.20

Two effective new antiviral drugs for SARS-CoV-2

Scientists at the Institut Pasteur have successfully synthesized two novel molecules that are active against several variants of the virus responsible for COVID-19. The discovery could inspire new families of antiviral drugs against future emerging viral diseases.

Événement | 2021.10.07

COVID-19, cancers, antibiotic resistance: meet the researchers at the Institut Pasteur

On the occasion of the 15th edition of the Pasteurdon, join the Institut Pasteur, on Thursday, October 7, in partnership with Figaro Partner, for an online program on the major current public health issues: COVID-19, cancers, antibiotic resistance. See you on October 7 on the Pasteurdon website.

Document de presse | 2020.03.19

CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine

Consortium to be led by the Institut Pasteur and will include Themis and the University of Pittsburgh.CEPI to provide initial US$4.9 million for consortium to develop a Covid-19 vaccine candidate based on measles-vector technology.Partnership becomes eighth Covid-19 vaccine development project that CEPI has signed since Jan 23, 2020 OSLO, NORWAY, March 19, 2020 – CEPI, the Coalition for...

News | 2021.05.06

Creation of the startup SPIKIMM to develop monoclonal antibodies as an innovative treatment for Covid-19

The Institut Pasteur has recently signed an exclusive worldwide license agreement with the new biotech start-up SpikImm SAS, created by Truffle Capital, for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies for therapeutic and diagnostic use.Monoclonal antibody therapy is one of the most innovative ways currently available to treat Covid-19 patients and prevent severe forms of...

News | 2020.06.04

Study reveals conditions for the onset of severe forms of COVID-19

Using state-of-the-art sequencing and bioinformatics techniques, scientists from the Institut Pasteur, working with fellow scientists from Israel and China, determined that patients with severe forms of COVID-19 presented an abnormal, ineffective lymphocyte response and a massive infiltration of inflammatory cells in the lungs.Patients with COVID-19 (see the COVID-19 fact sheet)present a...